|
Prescription Drug Search
Strengths available for Sandostatin multi dose vial:
Sandostatin multi dose vial 200mcg/mL
Sandostatin multi dose vial 500mcg/mL
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about CancerDrugsDirect.com
List of countries where we can ship Sandostatin:
- Algeria
- Armenia
- Bahamas
- Belize
- Bermuda
- Bolivia
- Brazil
- Cayman Islands
- Croatia
- Cuba
- Cyprus
- Czech Republic
- European Union
- Fiji
- Germany
- Gibraltar
- Greece
- Honduras
- Hungary
- India
- Iran
- Jordan
- Malta
- Moldova, Republic of
- Netherlands Antilles
- Norway
- Panama
- Paraguay
- Peru
- Saudi Arabia
- Spain
- Switzerland
- Tonga
- Tunisia
- Turkey
- United Arab Emirates
- United Kingdom, UK
- United States, US
- Uruguay
- Venezuela
Latest news releases on Sandostatin:
Novartis Scores in Phase III Study - Yahoo Finance
The randomized, double-blind phase III study, PASPORT-ACROMEGALY (PASireotide clinical trial PORTfolio - ACROMEGALY), compared the efficacy and safety of pasireotide LAR with Sandostatin LAR (octreotide/IM injection) in 358 treatment naïve ...
Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly - wallstreet-online.de
(ICE/ECE) in Florence, Italy[1]. Acromegaly is a rare endocrine disorder characterized by enlargement of the hands, feet and internal organs, as well as changes in facial structure[2], [3]. The majority of acromegaly cases are caused by a non-cancerous ...
New Drug Controls Growth Hormone Disease - MedPage Today
Patients were randomized to receive intramuscular injections of 40 mg long-acting pasiroeotide or 20 mg long-acting octreotide (Sandostatin) every 28 days for 1 year. Dose titration was permitted at three and seven months to 60 mg pasireotide or ...
Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone - pressreleasepoint.com
Patent expiries of blockbuster drugs such as Sandostatin LAR, Norditropin will restrict the growth of the market. The rapid uptake of novel dosage forms and formulations of existing drugs will increase the number of patients on treatment. Increased ...
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 - Yahoo Finance
504.2.3 Sandostatin LAR (octreotide acetate) 514.3 Key Takeaway 515 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment 525.1 Overview 525.2 Strategic Pipeline Assessment 525.3 Analysis by Phase of Development 535.3.1 Neuroendocrine ...
